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Translational toxicology: a developmental focus
for integrated research strategies
Claude Hughes1*, Michael Waters2, David Allen2 and Iyabo Obasanjo3
Abstract
Background: Given that toxicology studies the potential adverse effects of environmental exposures on various
forms of life and that clinical toxicology typically focuses on human health effects, what can and should the
relatively new term of “translational toxicology” be taken to mean?
Discussion: Our assertion is that the core concept of translational toxicology must incorporate existing principles
of toxicology and epidemiology, but be driven by the aim of developing safe and effective interventions beyond
simple reduction or avoidance of exposure to prevent, mitigate or reverse adverse human health effects of
exposures.
The field of toxicology has now reached a point where advances in multiple areas of biomedical research and
information technologies empower us to make fundamental transitions in directly impacting human health.
Translational toxicology must encompass four action elements as follows:
1) Assessing human exposures in critical windows across the lifespan
2) Defining modes of action and relevance of data from animal models
3) Use of mathematical models to develop plausible predictions as the basis for
4) Protective and restorative human health interventions.
The discussion focuses on the critical window of in-utero development.
Summary: Exposure assessment, basic toxicology and development of certain categories of mathematical models
are not new areas of research; however overtly integrating these in order to conceive, assess and validate effective
interventions to mitigate or reverse adverse effects of environmental exposures is our novel opportunity. This is
what we should do in translational toxicology so that we have a portfolio of interventional options to improve
human health that include both minimizing exposures and specific preventative/restorative/mitigative therapeutics.
Keywords: Translational toxicology, Environmental health, Biomarkers
Background
In the current genomics era, gene-environment interac-
tions provide the key to understanding health and dis-
ease. Human exposures to chemicals, physical agents
and social factors are inevitable and determining what
their subtle biological effect means to human disease is
difficult. Absence of evidence of (effect or harm) is not
evidence of absence (of effect or harm), particularly if ad-
verse outcomes are ecologically apparent in environmental
settings or in experimental animals following known ex-
posures. To minimize adverse health outcomes, regula-
tors, commercial entities, health care providers and the
general public need to know what exposures pose a sig-
nificant risk that merits intervention(s) to either reduce
exposure or mitigate effects.
Multiple factors in the environment impact human de-
velopment and subsequent health and disease. It has
long been appreciated that vitamins, minerals and other
essential nutrients play an important role in fetal growth
and development. For example, the essential role of fol-
ate (folic acid) in pregnancy and human development is
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well known. But apart from a modest number of other
well-known deficiencies, there is still limited under-
standing of the impact of micronutrient deficiencies or
inadequacies on the fetus and subsequent long-term
health outcomes [1]. Additionally, several socioeconomic
and societal factors are known to have important effects.
An unfolding example is the effect of maternal stress on
pregnancy outcome which is still being elucidated.
The appreciation of maternal stress and other aspects
of the social environment on the fetus has only recently
gained some mechanistic explanation. Animal research
suggesting transgenerational epigenetic programming of
genes (maternal imprinting) has been seen as an attract-
ive and plausible explanation. Recent reports in humans
and nonhuman primates show that epigenetic effects
may be sufficient explanations for such social effects.
Radtke et al. [2] analyzed the methylation status of ten
promoter sites for the glucocorticoid receptor (GR) gene
in mothers and their children 10 to 19 years after birth.
They paired those findings with the retrospective assess-
ment of maternal exposure to intimate partner violence.
Although the mother’s GR gene was not affected by that
profile of intimate partner violence, the methylation sta-
tus of the GR gene promoters of the adolescent children
was influenced by their mother’s experience during preg-
nancy. If maternal exposure to intimate partner violence
occurred during pregnancy, methylation of GR gene pro-
moters was increased three-fold in the offspring [2]. In a
broader profile of differential methylation of adult DNA,
Borghol et al. [3] found that disadvantaged socioeco-
nomic position in childhood was reflected in a change in
the level of methylation for over 1200 gene promoters.
While such a broad pattern of molecular effect does not
explicitly link a disadvantaged background to the well-
known adult mortality and morbidity risks, the findings
certainly sustain the view that this is a biologically plaus-
ible mechanism. In nonhuman primates, Tunga et al. [4]
used the social status (dominance rank) of female
macaques to demonstrate that dominance rank imposed
a widespread imprint on gene regulation such that
gene expression data could (in reverse) predict social
status with 80% accuracy. These remarkable correlations
between methylation patterns and dominance rank
strongly suggest that epigenetic molecular marks are a
key response to social status effects during development.
Taken together these human and nonhuman primate stud-
ies imply a distinct plausible association between social
influence and individual physiology at a molecular level.
Discussion
Transformation of human Toxicology into a translational
discipline: the translational gap
At present there is still a critical gap between laboratory
toxicology research and testing (i.e., molecular, cellular
and pathological outcomes in cell systems and animal
models) and epidemiological and ecosystem studies,
which examine exposed populations for disease. The
current bipartite approach fails to make adequately overt
the link between exposure(s) and clinical outcome(s). In
fact, most such claims of cause-and-effect are no better
than a tentative association of exposure and effect. So
we are typically left with both, a) inadequate evidence of
a plausible explicit risk due to an exposure, and b) inad-
equate evidence that there is no plausible explicit risk
due to an exposure and therefore limited intervention
possibilities. It is our objective to discuss current know-
ledge from research toxicology and epidemiological
studies on the occurrence of adverse events triggered
during critical life-span periods focusing on in-utero
development and how to plausibly mitigate adverse
health effects of these exposures particularly in terms of
endocrine/metabolic, neurodevelopment and reproduct-
ive consequences across the ensuing lifespan.
The public health imperative of endocrine and metabolic
disorders
If chemical exposures and stress influence the occur-
rence of endocrine mediated diseases, what is the poten-
tial public health impact? Golden [5] comprehensively
reviewed the clinical and public health significance of
54 endocrine and metabolic disorders in the US, and the
importance of any early in-life events that might impact
subsequent endocrine or metabolic function associated
with these disorders. Disorders with at least 5% prevalence
among adults included diabetes mellitus, impaired fasting
glucose, impaired glucose tolerance, obesity, metabolic
syndrome, osteoporosis, osteopenia, mild-moderate hypo-
vitaminosis D, erectile dysfunction, dyslipidemia, and
thyroiditis. Even if the less common endocrinopathies are
not considered, the high prevalence and incidence of com-
mon endocrine and metabolic disorders demonstrates the
profound adverse impact of endocrine diseases on longev-
ity, quality-of-life, public health and health care utilization.
Endocrine and metabolic disorders: childhood obesity
As the world has moved from agrarian, to industrial,
then information ages, the level of sedentary activities
open to humans have increased exponentially, which has
contributed to a global rise in obesity rates, affecting
both low and high income countries, as well as creating
wide variations within countries. In high income coun-
tries, the poor population is most affected while in low
income countries, the most affected are the middle class
[6]. This rise in obesity within populations forecasts an
increased burden from several diseases, most notably
cardiovascular diseases, diabetes, and cancers. Wang
et al. [7] used a simulation model to project an increase
of 65 million more obese adults in the US by 2030,
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coupled with in obesity-related medical costs reaching as
high as $66 billion per year.
Obesity seems to activate disease by acting through
sympathetic nervous activation. While the mechanisms
responsible for initiating the pathway remain to be
unequivocally elucidated, hyperinsulinemia, obstructive
sleep apnea, increased circulating cytokines, stress and
beta adrenergic receptor polymorphism are implicated
in the causal pathway to diabetes and most of the other
obesity related diseases [8]. For example, Chouchane
et al. [9] found expression of TNF-alpha and stress pro-
tein (hsp70-2) associated with obesity and that these,
and other endocrine disruptors, are most likely activated
along the pathway leading to disease; thus they are
potential targets for intervention. While diet and exer-
cise is still an important therapy, the fact that these two
simple interventions have not driven down the rising
wave of obesity means that additional interventions
are needed. Pharmacological interventions targeting the
sympathetic nervous system, either directly or indirectly,
may reduce disease outcomes and be useful along with
improved nutrition and increased exercise.
As childhood obesity has steadily increased, legitimate
public health concerns have been broadly raised. While
there is great concern, there also is uncertainty as to the
long-term health impact of this reality. On one hand,
Birch et al. [10] suggest that the common notion that
children will, “grow out of obesity,” is not true and that
critical environmental factors that affect children’s devel-
opment and obesity risks in their early years should be
modified in order to beneficially influence health and
well-being throughout life. On the other hand, there
remains a significant challenge to document whether
childhood obesity is or is not an independent risk factor for
adult metabolic syndrome, type II diabetes, or biomarkers
of the same (blood lipid status, insulin levels, etc.) [11].
Childhood obesity and In-utero environment Over
the last 20 years, childhood obesity has dramatically in-
creased globally with accompanying increases in child-
hood illnesses associated with obesity. Childhood obesity
leads to increased use of hospital services for several
obesity-related conditions when compared to normal
weight children [12]. More than a decade ago, Wang
and Deitz [13] estimated that the cost associated with
hospitalization for children due to obesity associated dis-
eases at around 127 million for the two year period ran-
ging from 1997 to 1999. Although obesity rates seem to
have stabilized among females 2 to 19 years since 1999,
it is still rising for males [14]. The associated health
costs will continue to go up because the effects of obes-
ity are cumulative causing more diseases and ill-health
over time if not reversed. There is evidence that adult
obesity is influenced by environmental factors and the
same is probably true for childhood obesity, including
prenatal and early postnatal environment. Salois [15]
describes an association between the built environment
(i.e., measures relating to food choice and physical
activity) and prevalence of obesity in low income
preschool children. There is an interaction between
modern sedentary lifestyles, nutrition and in utero and
early post-natal environments that influence the prob-
ability of childhood obesity. The in utero influences are
likely the result of sympathetic nervous system activa-
tion in mothers leading to disruption of various endo-
crine pathways in the developing fetus. The in utero
environment that triggers childhood obesity is not well
understood. Various sympathomimetic compounds may
be disrupting the in-utero environment and causing
receptor changes that interact with the postnatal envir-
onment to produce phenotypic obesity. Such changes
possibly could be detected in amniotic fluid. Possible
sympathomimetic candidate compounds include envir-
onmental phenols, fungicides, pesticides and their
metabolites, perfluorochemicals, phthalate metabolites
and some metals.
Childhood obesity and nutritional or metabolic
imprinting Epidemiological studies in human and ani-
mal experiments have shown that nutrition during fetal
and neonatal life may lead to obesity and its related dis-
orders in adulthood. There are no adequate models to
reproduce human situations. For example, milk formula
taken by infants during neonatal life may contain trace
compounds of sympathomimetics that may produce
subtle changes in receptor activation. Low birth weight
is considered the result of an adverse in utero growth
trajectory and is often associated with later metabolic
diseases in adult age. The hypothalamic-pituitary-ad-
renal axis (HPAA) and growth hormone/insulin-like
growth factor 1 (GH/IGF) axis may have a crucial role
in the regulation induced by nutritional programming.
The persistent alterations seem to be a consequence, at
least in part, of elevated insulin levels during “critical
periods” of pre- and early postnatal development. Like-
wise, leptin seems to play an important role in this com-
plex system. New knowledge about these mechanisms
suggests the development of new, rational, and effective
preventive and/or therapeutic options before and/or
after birth. Thus, early infancy may provide an oppor-
tunity for intervention aimed at reducing later disease
risk [16].
Effects of drugs and environmental chemicals on the
reproductive system
Clearly, drugs and environmental chemicals can adversely
affect the reproductive system. Available data indicate that
the consequences of exposure depend on the nature of the
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chemical, the dose of the chemical, its target, and the
timing of exposure relative to critical windows in develop-
ment of the reproductive system [17]. Toxicant exposures
may affect critical events in reproductive development,
ranging from early primordial germ cell determination to
gonadal differentiation, gametogenesis, external genitalia,
or signaling events regulating sexual behavior. Although
there are differences between the human reproductive
system and that of laboratory animal models, such models
have been extremely useful in assessing risks for key
human reproductive and developmental processes. The
objectives for future studies should include the elucidation
of the specific cellular and molecular targets of known
toxicants; the design of a systematic approach to the
identification of reproductive toxicants; and the develop-
ment of sensitive, specific, and predictive animal models,
minimally invasive surrogate markers, and/or in vitro tests
to assess reproductive system function during embryonic,
postnatal, and adult life. Integrated testing strategies will
be required to account for the many mechanisms associ-
ated with reproductive development that occur in vivo.
Evidence from animal models and human studies indi-
cates that many specific events can be perturbed by a
variety of toxicants, with endocrine-mediated mechanisms
being the more widely studied. Prioritized research needs
include basic studies on the cellular-molecular and endo-
crine regulation using expanded animal studies on different
classes of chemicals, comparing responses during develop-
ment (prenatal and postnatal) with responses in adults;
and, more extensive explorations regarding the reproduct-
ive biology and toxicology of puberty in humans [18].
Folic acid and autism Autism is a heterogeneous group
of complex developmental disabilities that result from a
number of possible etiologies. There is some debate
about the increasing prevalence of autism and whether
diagnosis of autism is increasing due to changing defini-
tions and parents influencing the medical system for
autism diagnosis for their children to access treatment
for other ailments [19]. The 2010 prevalence estimate
from meta-analyses of prevalence studies, 25 per 10,000,
is up from the 1970 estimate of 1 per 10,000 [19]. Diagnostic
and Statistical Manual of Mental Disorders (DSM) II was
in use in 1970 and had different criteria for diagnosing
autism from DSM IV-TR® in use in 2010. Diagnosis of
autism is complicated because patients often have other
co-morbidities such as seizures, GI problems, sleep disor-
ders and attention deficit disorders. The causes of autism
are still under active investigation with genetics, in utero
exposure to antiepileptic drugs (valproate) [20] and GI
bacteria being actively investigated as potential causes [21].
In utero hormonal disturbances are also indicted in
causation of autism [22] and this is thought to explain the
higher diagnosis of autism in males. High socio-economic
status (SES) has consistently been found to be associated
with autism but this could be due to under diagnoses in
families with low SES [23]. Wang and Leslie [24] found that
total expenditure for autism per child rose by 3.1% to
$22,772 between 2000 and 2003 using Medicaid data from
42 states.
In summary, developmental exposure to some envir-
onmental chemicals appear to directly adversely affect
neurodevelopment while other exposures that increase
the incidence of metabolic conditions in mothers may
be considered as an indirect cause as well. A recent pub-
lication indicates folic acid supplementation by mothers
around conception and during pregnancy reduces risk of
autism in children [25].
Use of biomarkers as endpoints
Numerous outcomes can be measured in human clinical
trials. Particularly in therapeutic clinical trials (such as
studies of pharmaceutical agents), investigators have the
luxury of designing the studies to permit measurement of
disease outcomes that would irrefutably demonstrate effi-
cacy or lack of efficacy of the study drug. Hand-in-hand,
alternative outcomes can be measured which are plausibly
linked to the disease outcomes but may or may not
be reliably associated with the ultimate outcome of
interest. This conundrum has led to a classification of
study outcomes (endpoints) that aids in the interpretation
of study results. The National Institutes of Health have
recommended definitions of outcome measures and
these were nicely summarized by Grimes et al. [26]
(See Table 1).
In our effort to develop a comprehensive approach to
translational toxicology, we cannot anticipate relying on
clinical endpoints that occur as a result of environmental
exposures as the primary sensor for determining cause
and effect relationships. Application of the precautionary
principle has a strong ethical basis when the exposures
of interest are unintended or unavoidable as occurs with
numerous environmental health concerns. A study sub-
ject can give informed consent to take a study drug but
individuals in an exposed population have given no such
consent. Therefore in translational toxicology studies we
can often expect to necessarily rely on surrogate end-
points or even biomarkers to drive decision-making and
interventions.
The spectrum of potential biomarkers that may have
utility in translational toxicology research is too broad to
list. Beyond chemical and molecular markers such as clin-
ical chemistry and hematology profiles, hormone levels
[27], a multitude of imaging techniques (radiology images,
ultrasound, CT, MRI, PET, etc.) can also be used. Histo-
pathology remains a key component in assessing target tis-
sue responses to exposures and new “-omics” technologies
such as transcriptomics, proteomics and metabolomics as
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well as next generation sequencing for mutations present
data sets that can serve as biomarker outcomes in various
toxicologic investigations across the lifespan. For example,
metabolomics have been applied to human embryonic
stem cell test systems to begin identifying biomarkers of de-
velopmental toxicity [28]. Global metabolite profiling
(untargeted metabolomics) allows the measurement of
thousands of compounds in minimal amounts of biological
material [29] and this technology can be applied broadly to
any number of toxicity research inquires. These same “old”
and “new” classes of biomarkers should be useful tools as
we strive to assess the impact of interventions that may be
implemented to mitigate the effects of prior or ongoing
toxicant exposure.
Within the realm of genomics and RNA signaling,
novel opportunities continue to arise. For example mi-
cro RNAs that are known to be key regulators of me-
tabolism have been shown to circulate and therefore
are available in accessible human specimens (blood) to
quantify as either signaling molecules or disease
markers [30]. Additionally, at the interface of molecular
and cellular biomarkers, the recent report by Kim et al.
[31] that the low levels of leukocyte mitochondrial
DNA copy number are reduced in postmenopausal
women with metabolic syndrome suggests that overt
links between molecular markers, cellular markers, tar-
get tissue function and disease outcomes can be expli-
citly linked.
Key developmental periods for interventions
Key intervals in the lifespan that may be taken as Win-
dows of Susceptibility (of adverse effects due to an ex-
posure) are also likely to be the key intervals for
intervention (Windows of Responsivity) to minimize,
negate or reverse antecedent or ongoing exposure ef-
fects. Those key intervals of dynamic biological change
during the lifespan that may be impacted by environ-
mental exposures are:
 early development [pre-conception, in utero,
neonatal, early childhood]
 peri-pubertal, and
 albeit in women only, the menopausal transition.
Effects of exposures can be one or more of the
following:
 Create a new syndrome
 Recreate a known “old” syndrome
 Increase the prevalence or severity of some extant
disease in an exposed population
 Exposure effects can interact with pre-existing
unrecognized (such as common under-diagnosed)
diseases, deficiencies, and other stressors to
exacerbate later disease outcomes, either prevalence
or severity.
There is also the possibility of unintended side-effects
of interventions during the windows of susceptibility
and this has contributed to reluctance to intervene dur-
ing these periods.
Early development More than a decade ago, the U.S. En-
vironmental Protection Agency convened a conference that
addressed the concept of critical windows during develop-
ment (preconception through puberty) when exposure to
xenobiotics may have the greatest adverse impact on subse-
quent health. The potential impact of developmental expo-
sures on reproductive health later in life [17,32] was judged
to be especially vulnerable due to the multitude of potential
cellular and molecular targets, the time dependency of es-
sential developmental events and the numerous modes of
toxicant action that can be anticipated. Key events occur
within gametes before fertilization, across embryonic and
fetal life, with additional maturational events occurring in
the perinatal period, and at puberty. Complex genomic,
hormonal, metabolic and growth signals are involved at
all stages. The workshop group advised that future stud-
ies should include the elucidation of the specific cellular
and molecular targets of known toxicants; the design of
a systematic approach to the identification of reproduct-
ive toxicants; and the development of sensitive, specific,
and predictive animal models, minimally invasive surro-
gate markers, or in vitro tests to assess reproductive sys-
tem function during embryonic, postnatal, and adult
life. Additionally, the panel emphasized that maternal
exposures or stressors that needed to be further
assessed included the following:
1. Psychosocial
2. Nutritional
3. Chemical exposures
4. Infectious disease exposures
Table 1 National Institutes of Health–recommended
definitions of outcome measures [26]
Outcome Definition
Clinical end point “A characteristic or variable that reflects
how a patient feels, functions, or survives.”
Surrogate end point “A biomarker that is intended to substitute
for a clinical end point. A surrogate end
point is expected to predict clinical benefit
(or harm or lack of benefit or harm) based on
epidemiologic, therapeutic, pathophysiologic,
or other scientific evidence.”
Biological marker
(biomarker)
“A characteristic that is objectively measured
and evaluated as an indicator of normal
biologic processes, pathogenic processes, or
pharmacologic responses to a therapeutic
intervention.”
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5. Inter-current diseases (in mother)
6. Concomitant medications
7. Maternal body composition (obesity/fitness).
All of these themes persist today as important and
inadequately defined areas of concern. As a single illus-
tration, there is a strengthening view that several devel-
opmental exposures are causally associated with obesity
later in life. Recent and ongoing epidemiological and
animal studies have shown that up to 20 chemical endo-
crine disrupters are potential causes of obesity in chil-
dren and adults if exposure occurs in early development
[33]. Stress on the mother and nutrition of the mother
have also been established to alter endocrine receptors
and lead to obesity in children [9,16] from epidemio-
logical and animal studies.
There is a need for further investigation to understand
where effective interventions could be applied such as
targeted nutritional guidance or active ways to reduce
exposures of concern including possible prescription
interventions for mother or child.
Peri-pubertal Given some recent studies showing that
interventions in late adolescent/early pubertal children
for risk of metabolic syndrome may have greater benefit
than somewhat later interventions, the peri-pubertal
interval may be a strong opportunity to show that envir-
onmental health impacts can be actively treated/miti-
gated/managed. A key concept is that the intrauterine
fetal environment has effects that manifest in the late
adolescent or pubertal interval.
In utero endocrinology and effects in adolescence
There is evidence in animals and humans that metabolic
syndrome, insulin resistance, obesity etc. as well as
female reproduction can be impacted by endogenous
intrauterine endocrine or metabolic exposures. Since a
number of animal studies had shown that exposure to
intrauterine hyperglycemia appeared to increase risk
factors for cardiovascular disease, Clausen et al. [34]
studied the risk of overweight and metabolic syndrome
in adult offspring of women who had diet-treated gesta-
tional diabetes or type I diabetes. These investigators
assessed over 1000 women and were able to show that
adult offspring of mothers with diet-treated gestational
diabetes or type I diabetes have an increased risk of
overweight and metabolic syndrome. These findings
raise the question as to whether caloric restriction dur-
ing gestation might reduce the risk of these adverse
metabolic outcomes for the offspring. A recent study in
rats [35], in which moderate caloric restriction of lactat-
ing rats was shown to protect from obesity development
in the offspring as well as other related metabolic
alterations, suggests that such a protective effect in
humans is at least plausible.
While there has been extensive consideration of poten-
tial effects of exogenous sex hormone-like compounds on
later reproductive potential of female offspring, less atten-
tion has been given to the potential effects of endogenous
sex steroids during the intrauterine interval. Hart et al.
[36] have addressed this question by assessing the impact
of maternal circulating androgen levels during normal
pregnancy on ovarian function, as determined by early
follicular phase antimullerian hormone (AMH) levels,
inhibin B levels, and antral follicle count (AFC) in 244
female offspring in adolescence. These investigators found
that maternal circulating total testosterone levels at
18 weeks gestation were statistically significantly corre-
lated with early follicular-phase circulating AMH levels in
female adolescent offspring, but no other statistically sig-
nificant correlations were determined among the maternal
androgens and the markers of adolescent ovarian function
at 18 or 34 weeks of gestation. Clearly such potential rela-
tionships between the intrauterine endocrine environment
and the subsequent markers of reproductive competency
in the peri-pubertal interval deserve further inquiry.
Menopausal transition The decade approximating age
40 to 50 years involves dynamic changes in reproductive
endocrine functions and is temporally something of a
“last chance” to preempt a number of risk profiles that
influence diseases that become progressively more
prominent in women after age 50–60. There is a moder-
ate amount of attention now to endocrine, nutrition and
lifestyle aspects of this life-stage, but virtually no atten-
tion is being given to the potential interaction of envir-
onmental chemical exposures with those themes. The
menopausal transition results in changes in hormonal
profile and changes in FSH, Inhibin B and AMH hor-
mone have been noted; disruption of this intricate
process may lead to abnormalities that could generate
into disease [27,37].
Documented human exposures from biomonitoring
programs: what compounds/classes might be implicated?
Chemical exposures of pregnant women: drugs, prescription
and OTC
The Food and Drug Administration (FDA) classifies drugs
according to the degree of risk they pose for the fetus if
they are used during pregnancy [38] (see Table 2).
As a general matter, obstetrical care of pregnant
women is precautionary and gravidas are discouraged from
using prescription pharmaceuticals and over-the-counter
(OTC) drugs to minimize exposure of the embryo or
fetus to these classes of exogenous chemicals. Reality dic-
tates that most women do in fact use one or more drugs
during a pregnancy. More than 90% of pregnant women
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take prescription or nonprescription (over-the-counter)
drugs or use social drugs (such as tobacco and alcohol) or
illicit drugs at some time during pregnancy [38]. For the
most part regarding this multitude of exposures, data are
inadequate to support either our fearful assumption of
fetal risk due to such exposures or to tacitly or explicitly
endorse selective usage of drugs by gravidas. Given that
common and presumptively safe drugs are also the
ones frequently used by gravidas, some publications
do document some of these in utero exposures and their
potential fetal effects.
Acetaminophen (APAP) is one of the most frequently
used drugs among pregnant women and is also the most
common drug overdose in pregnancy [39]. Nonetheless,
data regarding APAP overdose in pregnancy is limited
and consists mainly of case reports or a small series of
cases and there is no known threshold for occurrence of
toxic symptoms. APAP crosses the placenta and high
doses are known to be hepatotoxic. Hepatic metabolites
may cause fetal hepatic necrosis. Because N-acetylcysteine
(NAC) also crosses the placenta, some data suggest that
the majority of morbidity and mortality from APAP over-
dose can be averted by initiation of NAC within the first
16 hours of ingestion and possibly even later. It appears
that NAC does not itself pose any demonstrated risk to
the fetus, so the standard-of-care would be to administer
as early as possible after APAP overdosage in pregnancy.
Since the vast majority of usages of APAP are not over-
dosages, it has been important to determine if usage in
proper dosages is or is not associated with an increased
prevalence of congenital abnormalities and to determine a
threshold for toxicity. Rebordosa et al. [40] assessed
>88,000 pregnant women and their liveborn singletons
from the Danish National Birth Cohort who had informa-
tion on APAP use during the first trimester of pregnancy
and 4.3% of children from the cohort were diagnosed with
congenital abnormalities. Children exposed to APAP
during the first trimester of pregnancy (n > 26,000) did not
have an increased prevalence of congenital abnormalities
compared with nonexposed children (n > 61,000).
In another study, Snijder et al. [41] examined the
influence of maternal exposure to mild analgesics
during pregnancy on the occurrence of cryptorchidism
and hypospadia in >3000 offspring in the Netherlands
Generation R [birth cohort] Study. Cryptorchidism and
hypospadia were identified during routine screening
assessments performed in child health care centers by
trained physicians. The use of mild analgesics was
assessed in three prenatal questionnaires in pregnancy,
resulting in four periods of use, namely, periconception
period, first 14 weeks of gestation, 14–22 weeks of
gestation and 20–32 weeks of gestation. The prevalence
was 2.1% for cryptorchidism and 0.7% for hypospadia.
Use of mild analgesics in the second period of preg-
nancy (14–22 weeks) increased the risk of congenital
cryptorchidism [with adjusted odds ratios (OR) of
approximately 2] primarily due to the use of APAP. The
results suggest that intrauterine exposure to mild anal-
gesics, primarily APAP, during the period in pregnancy
when male sexual differentiation takes place, increases
the risk of cryptorchidism.
In summary, even for this extraordinarily common
drug (APAP), we have data that makes advice to a preg-
nant woman rather equivocal. Namely, we do not think
there is a risk of major congenital abnormalities if she
were to use APAP during pregnancy but there is a doub-
ling of risk of at least one congenital abnormality for
male infants if she uses APAP in mid-gestation. If APAP
is something of a “best case scenario” as regards having
known developmental exposures and known clinical out-
comes for the infants, the challenge to address all other
relevant exposures (drugs, environmental and dietary
chemicals, etc.) is indeed immense.
Arguably OTC drug usage could be deemed inessen-
tial, but some use of prescription drugs by pregnant
women is clinically-compelling or truly unavoidable to
assure her life and health. A prime example is the use of
antiepileptic drugs (AEDs) [42]. For women with seizure
disorders, many questions must be addressed even prior
to conception. To avoid injury or death for the mother
and the fetus, it may be impossible to stop or change the
AED regimen during pregnancy. In some few cases an
AED can be discontinued prior to conception, but this
requires attentive and expert medical care. Most women
with seizure disorders will require continued use of their
AEDs before, during and after pregnancy. In practice,
the aim is to prescribe the most effective AED while
minimizing risks, and avoiding polytherapy and valpro-
ate if possible. Additionally, the dosing regimens will
often require changes because drug metabolism of AEDs
Table 2 Categories of risk for drugs during pregnancy [38]
Category Description
A These drugs are the safest. Well-designed studies in
people show no risks to the fetus.
B Studies in animals show no risk to the fetus, and no
well-designed studies in people have been done.
or
Studies in animals show a risk to the fetus, but well-
designed studies in people do not.
C No adequate studies in animals or people have been done.
D Evidence shows a risk to the human fetus, but benefits of
the drug may outweigh risks in certain situations. For
example, the mother may have a life-threatening disorder or
a serious disorder that cannot be treated with safer drugs.
X Risk to the fetus has been proved to outweigh any
possible benefit.
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varies across pregnancy. Finally, the fetus faces risks due
to potential effects of the AEDs, but also from the
exposure to the concurrent maternal medical condition
per se (her seizure disorder).
Another category of clinically-compelling prescription
drug exposure in utero is antipsychotics. Antipsychotics
are being used in behavioral medicine well beyond
psychotic disorders to include depressive, bipolar, and
anxiety disorders. As a result, fetal exposure to this class
of compounds must be increasing in frequency, but any
neurodevelopmental sequelae of fetal antipsychotic
exposure is poorly understood. To examine whether
intrauterine antipsychotic exposure is associated with
deficits in neuromotor performance and habituation in
6-month-old infants, Johnson et al. [43] studied >300
maternal-infant dyads (N = 309) at 6 months postpartum
with pregnancy exposure to antipsychotics (n = 22),
antidepressants (n = 202), or no psychotropic agents
(n = 85). Examiners masked to maternal-infant exposure
status administered a standardized neuromotor examin-
ation (Infant Neurological International Battery [INFANIB])
that tests posture, tone, reflexes, and motor skills and a
visual habituation paradigm using a neutral female face.
Infants prenatally exposed to antipsychotics showed signifi-
cantly lower INFANIB scores than those with antidepres-
sant or no psychotropic exposure. These results indicate
that 6-month-old infants who were exposed to anti-
psychotic drugs in utero had lower scores on a standard test
of neuromotor performance suggesting that this was a
neurodevelopmental effect of fetal antipsychotic exposure.
Finally, a recent study by Daw et al. [44] provides a
broad and contemporary perspective of the extent of
prescription drug use by pregnant women. The investi-
gators assessed the frequency, timing, and type of medi-
cines used before, during, and after pregnancy in a
Canadian population. This retrospective cohort analysis
used population-based health care data from all preg-
nancies ending in live births in hospitals in British
Columbia from April 2001 to June 2006 (n = 163,082).
Data from hospital records were linked to those in
outpatient prescription-drug claims. Data from prescrip-
tions filled from 6 months before pregnancy to 6 months
postpartum were analyzed. Drugs were classified by
therapeutic category and FDA pregnancy risk categories.
Prescriptions were filled in 63.5% of pregnancies. At
least 1 prescription for a category D or X medicine was
filled in 7.8% of pregnancies (5.5% category D; 2.5%
category X). The most frequently filled prescriptions for
category D drugs were benzodiazepines and antidepres-
sants. The most frequently filled prescriptions for
category X drugs were oral contraceptives and ovulation
stimulants filled in the first trimester. Remarkably, these
data show that the majority of pregnant women in
British Columbia received at least 1 prescription, and ~1
in 13 received a prescription for a drug categorized as D
or X by the FDA.
This remarkable prevalence of maternal prescription drug
use emphasizes the need for thorough pharmacovigilance
and regulatory processes to assess potential fetal risks
before, during and after drug approval and marketing.
Additionally if a comprehensive translational approach is
to be realized in human developmental toxicology, this
category of fetal exposures must be included “in the mix”
along with other environmental and dietary exposures.
Despite the widespread use of benzodiazepines during
pregnancy and lactation, little information is available
about their effect on the developing fetus and on nursing
infants. Iqbal et al. [45] reviewed what is currently
known about the effects of benzodiazepine therapy on
the fetus and on nursing infants. Currently available
information is insufficient to determine whether the
potential benefits of benzodiazepines to the mother
outweigh the risks to the fetus. High peak concentra-
tions should be avoided by dividing the daily dosage into
two or three doses. Minimizing the risks of benzodiazep-
ine therapy among pregnant or lactating women involves
using drugs that have established safety records at
the lowest dosage for the shortest possible duration,
avoiding use during the first trimester, and avoiding
multidrug regimens.
Chemical exposures of pregnant women: environmental
and natural dietary chemicals
Pregnant women and infants are exposed to multiple
chemicals through the diet. These include naturally
occurring dietary components such as phytoestrogens
[46] as well as numerous synthetic compounds. The
online database TEDX (The Endocrine Disruption
Exchange 2013) [47] lists chemicals with the potential to
affect the endocrine system. To date there are approxi-
mately 1,517 endocrine disruptors on the TEDX List.
Quantifying some of these dietary exposures may rely
on survey instruments such as food frequency question-
naires as well as assays of biological specimens. Food
frequency questionnaires (FFQ) have been adapted to
provide a degree of quantification of soy consumption
[48] by adult women. Since soy is the primary source of
dietary estrogenic isoflavones in Western countries, the
demonstrated correlation of data from the FFQ and
plasma isoflavone concentrations indicate that either
technique may provide adequate documentation of levels
of exposure.
In recent years several different types of biological
specimens from pregnant women have been assayed for
environmental and natural dietary chemicals that are
known to or suspected to have hormonal activity. Engel
et al. [49] found detectable levels of three phytoestrogens
(enterolactone, daidzein and genistein) and bisphenol A
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(BPA) in 21 amniotic fluid specimens that were collected
before 20 weeks gestation. Samples were obtained by
amniocentesis from women who were referred to the
Mount Sinai Medical Center because of advanced mater-
nal age. The relative concentration of the chemicals in am-
niotic fluid were enterolactone > daidzein > genistein > >
BPA. Woodruff et al. [50] assessed exposure to environ-
mental chemicals during fetal development by analyzing
samples from pregnant women who were participants in
the National Health and Nutritional Examination Survey
(NHANES), a nationally representative sample of the U.S.
population. The investigators analyzed data for 163
chemical analytes in 12 chemical classes for subsamples
of 268 pregnant women from NHANES 2003–2004.
The percentage of pregnant women with detectable levels
of an individual chemical ranged from 0 to 100%. Certain
polychlorinated biphenyls, organochlorine pesticides, per-
fluorinated compounds (PFCs), phenols, polybrominated
diphenyl ethers (PBDEs), phthalates, polycyclic aromatic
hydrocarbons, and perchlorate were detected in 99–100%
of pregnant women. The median number of detected
chemicals by chemical class ranged from 4 of 12 PFCs to 9
of 13 phthalates. Across chemical classes, median number
ranged from 8 of 17 chemical analytes to 50 of 71 chemical
analytes. In general, levels in pregnant women were similar
to or lower than levels in nonpregnant women.
Chemical exposures of pregnant women: herbs and
supplements
An additional category of potential chemical exposure of the
human fetus that is neither drugs nor diet per se is the use
of herbal products and dietary supplements. A recent
national survey in the United States [51] demonstrates the
widespread use of these biologically active products. These
investigators assessed population and subpopulation changes
in rates of herb and supplement use and rates of disclosure
of herb and supplement use to conventional medical
providers and compared data from the 2002 (n = 30,427)
and 2007 (n = 22,657) Adult Complementary and Alterna-
tive Medicine File to the National Health Interview Survey
(NHIS). The number of adults in the United States that
ever used herbs or supplements was 55.1 million in
2007. The proportion of adults who reported use of
herbs or supplements in the past 12 months was 17.9%
in 2007. The proportion of respondents that disclosed
herb or supplement use to their physician or another
conventional medical professional was 45.4% in 2007.
However, <1% of recent herb and supplement users
disclosed this use to their pharmacist.
This study did not specifically address the question of
usage of herbal products and dietary supplements by
pregnant women and we are unaware of any reports
documenting whether pregnant women are comparable
to other adults in this regard.
Chemical exposures of pregnant women: smoking, ethanol
and drugs of abuse
While animal studies have shown that early life exposure
to cigarette smoke can have adverse effects on specific
body systems such as the CNS [52], the adverse impact
of tobacco (cigarette) smoking on the human fetus had
been documented by a number of studies over the last
three decades with most outcomes documented in terms
of birthweights and/or other general measures of in
utero growth. Wang et al. [53] reported on the relation-
ship of birth outcomes to the timing and intensity of
maternal active and passive smoking estimated both
from self-reports and from cotinine concentration in
maternal urine during early, middle, and late gestation.
Their study included 740 white and Hispanic women in
Boston, MA between 1986 and 1992. At each antenatal
visit, information on maternal active and passive smok-
ing was obtained by a detailed questionnaire, and by
measurement of urine cotinine concentrations. Infant
birth outcomes were obtained from hospital records. The
percentage of mothers who ever smoked cigarettes during
pregnancy was 55.5% for white and 10.2% for Hispanic
women. A significant inverse exposure-response relation-
ship between cotinine concentration in maternal urine
and infant size (birthweight, length and head circumfer-
ence) at birth was demonstrated. The relationship was
less clear between maternal self-reported smoking status
(both active and passive) and these fetal outcomes.
Additional studies have used various biological speci-
mens for assessment of fetal exposure to tobacco smok-
ing by measuring cotinine as the biomarker of exposure.
Maternal salivary cotinine levels (SCLs) were compared
to pregnancy outcomes among >700 pregnant women
including 126 active smokers [54]. In linear regression
analyses adjusting for sociodemographic and medical
factors, SCLs of >20 ng/mL were associated with a
reduction in birth weight of 88 g when SCLs were
measured at baseline (P = .042) and 205 g when SCLs
were measured immediately before delivery (P < .001).
These investigators concluded that at any cutoff level,
birth weight reduction was more significant for the same
SCL measured in late pregnancy. Dietz et al. [55]
analyzed data from the 1999–2006 National Health and
Nutrition Examination Survey and estimated the per-
centage of 994 pregnant and 3,203 nonpregnant women
20–44 years of age who did not report smoking but had
serum cotinine levels that exceeded the defined cut
point for active smoking (nondisclosure). Active smok-
ing was defined as self-reporting smoking or having a
serum cotinine concentration that exceeded the cut
point for active smoking. Overall, 13.0% of pregnant
women and 29.7% of nonpregnant women were active
smokers. Nondisclosure was higher among pregnant
active smokers (22.9%) than among nonpregnant
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smokers (9.2%). The investigators concluded that studies
and surveillance systems that rely on self-reported smok-
ing status are subject to underestimation of smoking
prevalence, especially among pregnant women, and
underreporting may vary by demographic characteristics.
In another study of fetal umbilical cord drug levels and
maternal self-report [56] in >100 specimens, there was
only fair agreement between self-reported smoking and
cotinine levels as well as slight agreement with current
drug use and positive drug levels. Compared with mater-
nal self-report, sensitivity of cotinine levels was 27% and
specificity was 98%. Sensitivity of positive cord illicit
drug levels was 32% and specificity was 85%.A clear
blunt summary of the adverse impact of tobacco smok-
ing on women and their infants can be viewed on the
Centers for Diseases Control website [57].
In terms of fetal exposure to ethanol, there is absolute
certainty that pregnant women should not consume
alcoholic beverages. This is a clear and certain case for
fetal protection by avoidance of exposure and is an
ongoing critically important public health message from
the American College of Obstetrics and Gynecology
[58]. A recent review and commentary by Tracy [59],
succinctly and powerfully documents the history of fetal
alcohol syndrome, the animal and human data indicating
that there is no safe level of exposure and that obstetri-
cians and other healthcare providers must be more
assertive in identifying and counseling reproductive age
women and especially those who are pregnant regarding
fetal risk. This is a clear case where the toxicology, social
norms and delivery of healthcare all make the course of
appropriate action clear; the human fetus should not be
exposed to ethanol.
Use of cocaine, marijuana, and other illicit drugs during
pregnancy has been associated with a variety of adverse
effects even though causality is not firmly proven. Effects
include low birth weight, neurodevelopmental deficits and
impairments affecting behavior, cognition, attention,
language, and learning skills plus other behavioral prob-
lems in children exposed to cocaine, marijuana or heroin
in utero. Methamphetamine exposure has been associated
with fetal growth restriction, decreased arousal, and alter-
ations in motor control in infants [60]. Neurotoxicity and
psychopathology associated with methamphetamines and
amphetamine exposure has been shown in both animal
and epidemiologic studies, with more severe effects in
women [61]. Given the high recreational use in young
adults, the effects in-utero on the developing brains needs
further investigation.
Endocrine disruption as a functional category of toxicants
The spectrum of possibly non-mutagenic but highly
specific modes of action of chemical toxicants is implied
by the molecular targets through which pharmaceuticals
have been shown to act. The notion that some environ-
mental and dietary compounds can act via highly
specific signaling pathways to elicit reproductive and/or
multifaceted developmental effects has led to appreci-
ation of more subtle effects of exposures in animal
models and raised suspicion that important developmen-
tal effects may be similarly occurring in humans that
have gone unrecognized in the past. The full range of
potential modes of action is captured in the “Guide to
Receptors and Channels” [62]. This compilation of the
major pharmacological targets is divided into seven
sections: G protein-coupled receptors, ligand-gated ion
channels, ion channels, catalytic receptors, nuclear
receptors, transporters and enzymes. Would all of these
actions be considered “endocrine disruption” or do we
simply need to consider “developmental toxicology” to
be the broader designation and limit “EDC” to those
compounds that bind to or affect hormone signaling
pathways per se?
Endocrine-disrupting chemicals (EDCs) can have
effects at low doses that are not predicted by effects at
higher doses [63]. Low-dose effects are those that occur
within the range of human exposures or those observed
at doses below the range used in traditional toxicological
studies. These effects may depend upon nonmonotonic
dose–response curves where a nonlinear relationship
between dose and effect where the slope of the curve
changes sign somewhere within the range of doses
examined. It is noteworthy that nonmonotonic re-
sponses and low-dose effects are remarkably common
in studies of natural hormones and EDCs. On this
basis, Birnbaum [64] has urged collaborations be-
tween research scientists in academia, government,
and industry to allow for development of more sophis-
ticated study designs to facilitate regulatory decisions.
Our core proposal is as follows:
In order to impact human health, the developmental
toxicology concept of endocrine disruption must be “put
to the test” in any instance where a scientifically valid
health concern is raised in which:
a) human exposure(s) occur,
b) there is a plausible mode of action such that the
exposure might elicit developmental effects,
c) human health outcomes are assessed and
d) both passive [reduce exposures] and active
[nutritional, sociobehavioral or pharmaceutical
interventions] health risk mitigation/intervention
strategies can be developed for exposed individuals.
What evidence and modes of action link exposure to
endocrine disruptors to endocrine or other human
diseases? An essential missing link between endocrine
disruptor testing and screening and epidemiology/
Hughes et al. BMC Pharmacology and Toxicology 2013, 14:51 Page 10 of 19
http://www.biomedcentral.com/2050-6511/14/51
population-based exposure assessments is individualized
assessments of exposures and effects that are plausibly
linked via known modes-of-action. Because metabolomic
methods allow a broad look at multiple potentially
perturbed metabolic pathways (and implictly different
modes-of-action), and multiple biospecimens can be
assayed [some of which are quite non-invasively
obtained; urine], this may prove to be the preferred core
analytical method for defining these individualized
exposure-effect relationships.
What modes of action are known or are plausible from
animal, in vitro, and human clinical data?
Numerous biological processes and multiple levels of
biological organization could be adversely impacted by
exposures to exogenous chemicals and thereby affect
fetal-neonatal development and measurable endpoints
(see Table 3). These modes or sites of action include
stem cell/progenitor cell numbers or lineages mutation,
epigenetics, higher level effects on target tissue or body
system(s) organization, stressors that affect CNS, inflam-
matory or immune pathways, etc.
Stem cell mediated effects
One plausible target of toxic action in almost any target
tissue during development is the stem or progenitor cell.
Any exposure that might alter the population size or
characteristics of stem or progenitor cells could have
profound and lasting effects on the structural and func-
tional integrity of any target tissue, organ or system.
Additionally, since tools have been developed to study
stem cells, the questions about potential actions of toxi-
cants can now be investigated in relatively direct ways.
In particular relationship to developmental effects of
fetal exposures, stem cell populations from umbilical
cord blood present a unique and well appreciated oppor-
tunity for study [65]. Umbilical cord blood contains at
least three populations of stem cells, each with unique
features and properties.
Hematopoietic stem and progenitor cells continuously
egress out of the bone marrow (BM) and into the circu-
lation under homeostatic conditions. This process is
dramatically enhanced during stress situations and
induced mobilization regimens [66]. Recent studies have
clearly identified that hematopoietic stem cells (HSC)
are part of a hierarchical organization defined by cells
able to initiate long-term repopulation (LT-HSC) of
injured BM followed by populations with transient
repopulation ability [67]. As HSCs are able to supply
blood cells for the lifespan of the individual, LT-HSCs
undergo an aging process. The consequences of aging
are an increase in the stem cell pool size, increased self-
renewal and production of cells with expression of
myeloid-specific genes and genes commonly expressed
in myeloid leukemia. The age-related increased inci-
dence of myeloproliferative disorders is therefore not
surprising. Marrow cells circulate and migrate to a num-
ber of different organs. Previously assumed tissue and
organ specificities appear to be less stringent and primi-
tive cells residing in one organ may contribute to the
structural and functional regeneration of other organs. It
is intriguing to speculate that cells and cytokines used in
Table 3 Developmental toxicology endpoints
Endpoints Methods of measurement
General growth, morphology of body
regions, organs and tissues
Classical teratology
Organization of organs & tissues Microscopic veterinary or human pathology
Cellular composition of tissues Relative composition of major cell types; histopathology, histochemistry, histomorphometry
Finer cellular and tissue profiles Tissue content of stem cells and progenitor cells; inflammatory/migratory cell populations;
extracellular matrix/ cell matrix interactions; assess cell cycle kinetics, critical cellular process
(e.g., apoptosis and autophagy)
Molecular changes within cells DNA, RNA, proteins (including processing, turnover, etc.), lipids and glycosylation; genomics,
epigenomics, transcriptomics, microRNAs/siRNAs
“Accessible” or “translatable” (can be used
in lab models and in humans) biomarkers
- Imaging (ultrasound, MRI, CT, etc.)
- Functional assessments (behavior, treadmill, learning, cognition, renal function studies,
lung function studies, grip strength, etc.)
- Tissue biopsies, male and female gametes/follicular fluid; amniotic fluid; blood, urine
- Routine chemistries, hematology,
- Circulating cells (e.g., bone marrow stem cells, leukocytes, other stem/progenitor cells)
Biomolecules in blood plasma, urine including
macromolecules, small molecules
- Specific assays for individual molecules
- “Broad Net” approaches of proteomics, metabolomics, siRNAs, etc.
Integrative Physiology/Systems Biology Multiple opportunities to link in vitro and animal models to humans and to use mathematical
models to dynamically integrate multiple biological parameters
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appropriate concentrations may be able to repair dam-
aged organs by using the defective organ as a scaffold,
thus reducing the need for the transplantation of solid
organs.
Evidence suggests haematopoietic stem cells (HSCs)
can migrate to injured liver and influence tissue repair.
However, Kavanaugh et al. [68] found that administered
HSCs homed predominantly to lungs rather than liver,
highlighting a potential therapeutic hurdle. Stem cells
are potential targets of intervention as well as possibly
targets of toxic agents.
Mutagenesis and alteration of gene expression
As a result of extensive collection of genome-wide tran-
scriptional expression data from cultured human cells
treated with bioactive small molecules, “The Connectiv-
ity Map (also known as cmap) has been assembled by
use of simple pattern-matching algorithms [69]. This
system enables the discovery of functional connections
between drugs, genes and diseases through the transitory
feature of common gene expression changes. At present
the interface provides access to the current version
(build 02) of Connectivity Map which contains more
than 7,000 expression profiles representing 1,309 com-
pounds. While not directly focused on toxicology or
development, this broad and comprehensive approach
toward characterizing the actions of chemicals on cells
will surely be the type of valuable tool that will facilitate
understanding the impact of toxicant exposures and
potential mitigation strategies.
The types of advances being made are illustrated by
recent work in hepatocellular carcinoma (HCC), the fifth
most common cancer worldwide. HCC is more preva-
lent in men than women and recent genetic studies
have revealed a causal role for androgen receptor (AR)
in hepatocarcinogenesis, but the underlying molecular
mechanism remains unclear. Feng et al. [70] used gen-
ome wide location and functional analyses to identify a
critical mediator of AR signaling via cell cycle-related
kinase (CCRK). Their results reveal a direct AR transcrip-
tional target, CCRK, which promotes hepatocarcinogenesis
through the upregulation of beta-catenin/TCF signaling.
Epigenetic changes
The field of toxicogenomics is undergoing remarkable
expansion due to advances in genomic technologies as
well as an expanding set of concepts about how environ-
mental agents may impact gene regulation and heritabil-
ity of traits. The epigenetic bases for heritable changes
in gene expression (without accompanying alterations in
the DNA sequence) are becoming more certain as
mechanisms such as DNA methylation, histone modifi-
cations, non-coding RNAs, and changes in expression or ac-
tivity of histone acetylases (HAT) and histone deacetylases
(HDAC) in the regulation of gene expression patterns
are elaborated [71]. It is becoming clear that epigenetic
mechanisms play a critical role in normal development
and differentiation and if disordered, may lead to dis-
eases such as cancers. The growing body of evidence
that environmental exposures especially in early devel-
opment can induce epigenetic changes implies that
these mechanisms will help explain toxicological effects
of environmental exposures. Additionally, epigenetic
changes are likely to explain a number of later-in-life
effects of early-in-life exposures as well as effects in
one or more subsequent generations.
The global prevalence of obesity is increasing across
most ages in both sexes. Ng et al. [72] found that pa-
ternal high-fat-diet (HFD) exposure programs B-cell
‘dysfunction’ in rat F1 female offspring. This report
demonstrates that non-genetic, intergenerational trans-
mission of the metabolic sequelae of a HFD from the
father to his offspring occurs in mammals. Thus paternal
as well as maternal exposures can bring about epigenetic
alterations that influence the metabolic competency of
their offspring.
Mathers et al. [73] summarized current knowledge of
the impact of dietary, lifestyle, and environmental deter-
minants of cancer risk and proposes that effects of these
exposures might be mediated, at least in part, via epigen-
etic mechanisms. Evidence is presented to support the
hypothesis that all recognized epigenetic marks (including
DNA methylation, histone modification, and microRNA
(miRNA) expression) are influenced by environmental
exposures, including diet, tobacco, alcohol, physical activ-
ity, stress, environmental carcinogens, genetic factors, and
infectious agents which play important roles in the
etiology of cancer. Given the plasticity of epigenetic marks
in response to cancer-related exposures, such epigenetic
marks are attractive candidates for the development of
surrogate endpoints which could be used in dietary or
lifestyle intervention studies for cancer prevention. The
authors argue that research should focus on identifying
epigenetic marks which are (i) validated as biomarkers for
the cancer under study; (ii) readily measured in easily
accessible tissues (e.g., blood, buccal cells, or stool); and
(iii) altered in response to dietary or lifestyle interventions
for which there is convincing evidence for a relationship
with cancer risk.
Transient environmental influences, such as perinatal
nutritional stress, may induce deleterious metabolic
symptoms that last for the entire life of individuals,
implying that epigenetic modifications play an important
role in this process. Jousse et al. [74] investigated, in
mice, the consequences of maternal undernutrition
during gestation and lactation on DNA methylation and
expression of the leptin gene, which plays a major regu-
latory role in coordinating nutritional state with many
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aspects of mammalian biology. The investigators found
that animals born to mothers fed a low-protein-diet
(F1-LPD group) have a lower body weight/adiposity and
exhibit a higher food intake than animals born to mothers
fed a control diet (F1-CD group). These modifications
persisted throughout life and were associated with lower
levels of leptin mRNA and protein in starved F1-LPD
mice, emphasizing that maternal protein-undernutrition
affects the balance between food intake and energy ex-
penditure in adults. Moreover, this nutritional stress
resulted in the removal of methyl groups at CpGs lo-
cated in the promoter of leptin, causing a permanent
specific modification in the dynamics of the expression
of leptin, which exhibits a stronger induction in the
F1-LPD than in F1-CD mice in response to a meal.
This study is an example of a molecular rationale
linking transient environmental influences to perman-
ent phenotypic consequences.
Histone modifications are thought to regulate chroma-
tin structure, transcription and other nuclear processes.
Histone methylation was originally believed to be an
irreversible modification that could only be removed by
histone eviction or by dilution during DNA replication.
However, the isolation of two families of enzymes that
can demethylate histones has changed this notion [75].
The biochemical activities of these histone demethylases to-
wards specific Lys residues on histones, and in some cases
non-histone substrates, have highlighted their importance
in developmental control, cell-fate decisions and disease.
Their ability to be regulated through protein-targeting com-
plexes and post-translational modifications is also begin-
ning to shed light on how they provide dynamic control
during transcription.
O-GlcNAcylation, which is a nutrient-sensitive sugar
modification, participates in the epigenetic regulation of
gene expression. Thus, O-GlcNAc cycling may serve as
a homeostatic mechanism linking nutrient availability to
higher-order chromatin organization [76]. The wide
range of physiological functions regulated by O-GlcNAc
cycling suggests an unexplored nexus between epigenetic
regulation in disease and nutrient availability.
To elucidate the role of age-related epigenetic changes in
healthy ageing and potential longevity, Bell et al. [77] stud-
ied the association between whole-blood DNA methylation
patterns in 172 female twins aged 32 to 80 with age and
age-related phenotypes. Genome-wide analyses assessed
differentially methylated regions (DMRs) for sixteen age-
related phenotypes (ap-DMRs) and chronological age
(a-DMRs). The majority of age-related changes in DNA
methylation were not associated with phenotypic measures
of healthy ageing in later life. Their results suggest that in a
small set of genes DNA methylation may be a candidate
mechanism of mediating not only environmental, but also
genetic effects on age-related phenotypes.
Translational research: biomarkers as a key component
Translatable biomarkers (e.g., true in animals and
humans; such as hemoglobin or pulse rate) or biomarker
equivalency/ pairings (organ weights or dimensions in
animal models vis-à-vis CT, MRI or ultrasound imaging
in humans) must be utilized but prudently. To advance
understanding of whether exposures have effects that
may be a risk, various molecular and imaging bio-
markers have been developed, proposed and used in
both laboratory and epidemiological settings. A critical
shortcoming in this tactic is that a biomarker result is
interpreted as a validated proxy for a clinical outcome.
This assumption or interpretive leap is virtually always
wrong. In human health research, the outcomes that
truly matter are clinical endpoints (how a patient feels,
functions or survives). Short of directly measuring clin-
ical endpoints, surrogate endpoints can be measured if
such surrogate endpoints have been validated. At a mini-
mum for biomarkers to be plausibly interpreted as indi-
cators of clinical endpoints, such biomarkers must be
explicitly validated as predictors of surrogate endpoints.
There are numerous such sets of endpoints and bio-
markers that are used in medical practice with varying
degrees of reliability. To illustrate, a few common exam-
ples would be as follows:
Clinical endpoint: sepsis
Surrogate endpoint: bacteremia
Biomarker: fever
Clinical endpoint: prostate cancer
Surrogate endpoint: microscopic pathology
Biomarker: prostate specific antigen (PSA)
Clinical endpoint: bone fractures
Surrogate endpoint: bone mineral density
Biomarker: osteocalcin (OC), trimeric carboxyterminal
telopeptide (ICTP).
In environmental health research, we cannot have
control over several key components in the “usual” hu-
man health research setting. Key characteristics of both
the exposure (the agent, dose, duration, route, etc.) and
the exposed subject (person’s age, sex, developmental
lifestage, intercurrent illnesses, nutritional status, etc.)
are not controlled by the investigator. So, for environ-
mental health research where the aim is to assess pos-
sible human health effects of exogenous exposures, how
can we approximate a thorough validation process of
linking biomarker(s) to surrogate endpoint(s) to clinical
endpoint(s)? We must transform the usual logic of
“translational” health research into an approach that
“works” to move toxicology research into actionable
environmental health discoveries.
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The aim of translational toxicology is to advance envir-
onmental health sciences in order to:
1. Transform Research & Development programs,
especially endocrine disrupter programs, to link
them overtly to disease outcomes;
2. Link target tissue/organ/system outcomes in animal
models to animal biomarkers (mostly molecular) to
human biomarkers to human target organ outcomes
(pathology, imaging and functional)
3. Enhance predictive use of animal and human
biomarker data sets by development of
circumscribed computational (mathematical,
statistical, knowledge-base, even simple schematic)
model development.
Timing of interventions for prevention or mitigation
We do need to consider that there may need to be
sustained, continuing interventions for certain adverse
effects/disease predispositions that are the result of
environmental exposures. Nevertheless, key windows for
interventions are likely to be the same as those in which
adverse effects are elicited. Thus, in utero/neonatal/early
childhood, adolescent/peri-pubertal and then meno-
pausal transition in women may be particularly respon-
sive since organizational/re-organizational processes are
biologically dynamic in those intervals.
What are the prospects for screening pregnant women
for exposures of concern and then implementation of
mitigation strategies? Perhaps the current compliance of
obstetrical practices in terms of testing in prenatal care
is a guide. Siddique et al. [78] examined whether the
frequency of four screening tests during prenatal care
conforms to evidence of effectiveness. The investigators
estimated rates of urine culture, anemia screening, oral
glucose tolerance test (OGTT), and urinalysis during
prenatal care by use of national probability samples of
office visits to physicians (National Ambulatory Medical
Care Survey) and to hospital outpatient departments
(National Hospital Ambulatory Medical Care Survey)
from 2001 to 2006. These data were compared to rec-
ommendations from the U.S. Preventive Services Task
Force (USPSTF). On average, women received a urine
culture in less than half of pregnancies. Women received
just over one anemia screening on average per preg-
nancy. From 2001–2003, women received an average of
5.6 urinalyses per pregnancy; the average dropped to 4.3
urinalyses per pregnancy in 2004–2006. On average,
women received just under one OGTT per pregnancy.
Compared to younger white women, minorities and
older women tend to get more anemia screenings, urine
cultures, and OGTTs. Compared to USPSTF recommen-
dations, too few women are receiving a urine culture
during prenatal care. In contrast, women receive far too
many urinalyses, but the rate appears to be falling.
Anemia screening conforms closely to recommenda-
tions. The USPSTF does not recommend for or against
universal diabetes screening using OGTT. Women
appear to receive OGTT routinely.
Obstetrical examples of interventions for fetal/neonatal/
lifelong well-being
“Fetal therapy is broadly defined as any intervention
administered to or via the mother with a primary indica-
tion to improve perinatal or long-term outcomes for the
fetus or newborn.” [79]. Due to concern about unknown
consequences of fetal exposures, many leaders of public
and private research entities, scientists, regulators and
non-obstetrical physicians believe that no pharmaceut-
ical interventions should be given to pregnant women
for the purpose of enhancing lifelong well-being of the
mother’s offspring. Beyond immunizations, care of ma-
ternal acute and chronic illnesses and specific obstetrical
conditions (e.g., pre-eclampsia, gestational diabetes, etc.)
including antenatal corticosteroids to enhance fetal lung
maturity when premature delivery is anticipated, there
are at least five different treatments that are commonly
given to pregnant women where a primary aim is to
effect fetal benefit that will obviously or likely manifest
across the lifespan (see Table 4).
Two studies by Ibanez et al. [96,97] suggest that the
peri-pubertal interval may be an important developmen-
tal window in which therapeutic interventions can
be safely and effectively administered to mitigate the
adverse health impact of earlier exposure to develop-
mental stressors. Low-birthweight (LBW) girls with pre-
cocious pubarche (PP) are at risk for an early menarche
(<12 years), an adult stature below target level, and
PCOS. Hyperinsulinemic insulin resistance is thought to
be a key factor. Therefore Ibanez et al. [96] studied the
effects of early metformin treatment on menarche,
height, and polycystic ovary syndrome (PCOS) markers
as an open-label, randomized study in thirty-eight LBW-
PP girls. At age 8 years, girls were randomly assigned to
remain untreated or to receive metformin for 4 years;
subsequently, both subgroups were followed without
treatment until each girl was postmenarcheal. At last
assessment, girls in each subgroup were on average
2 years beyond menarche; the mean growth velocity was
below 2 cm/years. Age at menarche was 11.4 ± 0.1 years
in untreated girls and 12.5 ± 0.2 years in metformin-
treated girls; the latter girls were taller and much leaner
(with less visceral and hepatic fat) and had more favor-
able levels of circulating insulin, androgens, and lipids. The
conclusions were that early metformin therapy (age ∼ 8–
12 years) delayed menarche; augmented postmenarcheal
height; reduced total, visceral, and hepatic adiposity; and
curbed the endocrine-metabolic course of LBW-PP girls
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away from adolescent PCOS. In their second study, Ibanez
et al. [97] compared the capacity of early vs. late metformin
treatment to prevent adolescent PCOS. This was a ran-
domized, open-label study over 7 yr in the thirty-eight
LBW-PP girls who were followed up from the mean age 8
until age 15 yr. Early metformin was study yr 1–4; age 8–
12 yr while late metformin was yr 6; age 13–14 yr. None of
the girls dropped out of the study. At age 15 yr, early-
metformin girls were taller (4 cm), were in a less
proinflammatory state, and had less central fat due to re-
ductions in visceral and hepatic fat. Hirsutism, androgen
excess, oligomenorrhea, and PCOS were between 2- and
8-fold more prevalent in late- than early-treated girls. Ab-
dominal adiposity was the first variable to diverge (at age
8–10 yr) between girls without vs. with PCOS at age 15 yr.
The investigators conclude that in LBW-PP girls, early
metformin therapy was found to prevent or delay the de-
velopment of hirsutism, androgen excess, oligomenorrhea,
and PCOS more effectively than late metformin. They
suggest that the time window of late childhood and early
puberty may be more critical for the development, and
thus for the prevention, of adolescent PCOS than the first
years beyond menarche.
Concluding remarks
We need to broadly reorient perspectives to make toxi-
cology and/or environmental health an active human
health-promoting process. We cannot continue to rely
on the existing dichotomy; on one hand, we have
laboratory-based molecular, cellular and animal models
data while on the other hand we have epidemiological
and exposure assessment data. We are convinced that
linking these types of data and scientific insights can be
done and this is the crux of moving toxicology into an
active translational research and interventional science.
Hormone signaling pathways may serve as mediators
of reproductive and developmental effects and earliest
indication of exposure. These early exposures may have
later effects which may differ across the lifespan depend-
ing on other critical hormonal activities in the body.
Exposures are inevitable and the body either builds or
has resilience or resistance to the adverse effects, or due
to earlier exposures losses its ability to resist and
succumbs to disease. The earlier exposures that cause
the body to lose its ability to avoid disease in response
to environmental factors needs to be evaluated.
Stem/progenitor cell populations must be a key com-
ponent to recovery/resilience to insults and provide a
capacity to recover/respond/heal either from the expos-
ure of interest or to multiple future or concurrent insults
later in development or across the lifespan.
Lab animals, ecological (wildlife) exposures, compan-
ion animals, and livestock can serve as bio-monitors and
formal ways of getting observations from these popula-
tions into the knowledge base on human relevance need
to be adopted.
A number of contemporary analytical techniques are
available to detect and quantify exposures and effects.
These methodological tools are widely called “biomarkers”
and cover a rather wide range of techniques/technologies
Table 4 Treatments commonly given to pregnant women for fetal benefit across the lifespan
Disease/Indication Treatment Outcome Selected references
Neural tube defects Folate Reduction in risk of neural
tube defects
American Academy of Pediatrics
Committee on Genetics [80]
U.S. Preventive Services Task
Force [81]
Vision and cognitive
function
Docosahexaenoic
acid (DHA)
Support optimal visual and
cognitive development
Koletzko et al. [82]
Smoking Nicotine and/or
N-acetylcysteine (NAC)
Smoking cessation and/or
chemoprevention of DNA
(and other) damage
Coleman et al. [83]
De Flora et al. [84]
Van Schooten et al. [85]
Maternal (and fetal)
hypothyroidism
Thyroid hormone therapy Avoid potential damage to
neural development
Abalovich et al. [86]
Rivkees & Mandel [87]
Shields et al. [88]
Kuppens et al. [89]
Lazarus et al. [90]
Cerebral palsy associated
with preterm delivery
Magnesium sulfate (MgSO4) Reduction in risk of cerebral
palsy/ motor disorders in
childhood
Nelson & Grether [91]
Rouse et al. [92]
Conde-Agudelo & Romero [93]
Rouse [94]
Doyle et al. [95]
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from DNA sequences of individual genes, to FACS of cell
subpopulations, to 3-D reconstruction of tissues and
organs from pathology slides, to whole body imaging with
CT and/or fMRI, etc. Techniques such as “shotgun” prote-
omics and metabolomics offer further broad scope
approaches for assessing responses of cells, tissues or
organisms to external signals or stressors. Appropriate
recognition of how biomarkers relate to disease outcomes
in humans is critical to moving environmental toxicology
from its current state to producing effective intervention
strategies.
How do we best develop and gain insight by compari-
sons of critical windows in animal/cellular models to
understand the human consequences for effects and the
opportunities for protective interventions?
Because exposures occur to many individual compounds,
classes of compounds and combinations (mixtures) of
compounds and raise legitimate concern, translational links
need to rely on various types of biomarkers that address
two types of causal toxicopathologic pathways.
1. The one (or ones) that are known modes of action
of the compound(s) such as most of the EPA
Endocrine Disruptor Screening Program Tier 1
Screening Assays [98].
2. The possibility of unknown modes of action such as
most of the EPA Endocrine Disruptor Screening
Program Tier 2 Testing Assays [99] or use of
metabolomics [99,100].
Number 1 is the “silver bullet” or “searching for the
lost keys under the lamp-post” while number 2 is “cast-
ing the broad net upon the waters” or “searching in the
dark.” Both need to be done. Number 1 because it relies
on using all that we know to trace a straight line be-
tween exposure, effect and prospects for mitigation;
number 2 because chemicals (even those highly selected
to have a very specific action via even a single molecular
process, e.g., drugs) have actions in multiple molecular/
cellular sites, and biological organisms and components
are rife with pleiotropic and redundant systems. So,
techniques that broadly ask what effects might result
from exposures are essential for translational toxicology.
The sorts of techniques that can “cast a broad net” to
possibly let us see (previously) unknown modes of action
include metabolomics, some forms of proteomics, assays
of mutagenic and epigenetic effects, stem cell/progenitor
cell/cell fate/cell sorting methods, histomorphometry
and advanced microscopy techniques, circulating mole-
cules (hormones, microRNAs, etc.), anatomical and
functional morphology imaging methods. These ap-
proaches must be core components of the research and
development strategy if translational environmental
health is to advance and favorably impact public health.
Summary
1. The pregnant woman and her fetus are exposed to
many chemicals. These chemicals include
environmental chemicals, dietary components, over-
the-counter drugs, prescription drugs, substances of
abuse (tobacco, alcohol and drugs of abuse) and
herbal and related products.
2. Any of these may affect the fetus via many potential
modes of action such as epigenetic, mutational,
endocrine, stem cell, and a multitude of other
signaling pathways (G protein receptors, ion
channels, etc.).
3. We will depend upon use of biomarkers to assess
actions of those compounds and to establish
meaning for clinical outcomes. Readily measured
biomarkers will have to be linked to surrogate
outcomes which have to be representative of clinical
outcomes.
4. In order to give substance to the term
“translational”, we must develop ethical and effective
interventions to complement exposure reduction so
that the adverse health effects of exposures can be
prevented, reversed or mitigated.
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